Navigating COA Complexities For A Psoriatic Arthritis Trial

A biotechnology firm reached out to Signant, seeking its advanced electronic clinical outcome assessment (eCOA) solutions and its profound proficiency in digital health science and scalable management. The objective was to fortify the measurement strategy for a comprehensive global Phase II trial focused on psoriatic arthritis. Within the ambit of this study's intricate protocol, a total of 18 clinical outcome assessments (COAs) were mandated for electronic data capture. Notably, among these assessments were those indispensable for evaluating the American College of Rheumatology (ACR) response criteria, a pivotal primary endpoint.

Executing this endeavor demanded a meticulously orchestrated schedule of activities, marked by meticulous planning and seamless collaboration. Such intricacies necessitated an adept grasp of scale management principles and innovative project delivery solutions, areas in which Signant had honed its expertise. The challenges posed by the study's multifaceted demands were met head-on, as Signant had primed itself to provide not only technology-driven solutions but also holistic support and creative problem-solving that resonated with the unique requirements of the trial.

Download the case study below to learn how Signant’s scale management expertise was able to help the sponsor navigate complexities related to COA selection, acquisition, and implementation and launch their psoriatic arthritis trial on time.